Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 7 of 7 results for bacillus calmette-guerin

  1. Synergo for non-muscle-invasive bladder cancer (MTG61)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

    Medical technologies guidance
    Published
    30 November 2021
    View recommendations

    Sections for MTG61

  2. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

    Medtech innovation briefing
    Published
    4 February 2021

  3. Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)

    Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.

    Interventional procedures guidance
    Published
    30 January 2019
    View recommendations

    Sections for IPG638

  4. Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)

    Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder.

    Interventional procedures guidance
    Published
    19 September 2018
    View recommendations

    Sections for IPG628

  5. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

    Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.

    Interventional procedures guidance
    Published
    24 July 2019
    View recommendations

    Sections for IPG656

  6. Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)

    NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .

    Medtech innovation briefing
    Published
    3 May 2022

  7. Tuberculosis (QS141)

    This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.

    Quality standard
    Published
    10 January 2017
    View quality statements

    Sections for QS141